Gene Therapy Regulation at Academic Medical Centres: What MUG-Linked Trials Signal

A Convergence Worth Reading Carefully

In September 2023, ICH S12 — the harmonised guideline on nonclinical biodistribution considerations for gene therapy products — came into effect under EMA/CHMP/ICH/318372/2021. The guideline reflects the growing regulatory maturity of gene therapy development, a field that continues to move from early-stage research towards increasingly structured clinical and commercial pathways. Academic medical centres are likely to play an important role in this transition, particularly where they participate in sponsored trials, investigator-initiated studies or collaborative development programmes involving investigational gene therapy products. The Medical University of Gdańsk operates within a research and clinical trial ecosystem in which such products may increasingly be encountered at the investigational stage. At this intersection, the regulatory and scientific information requirements can be more complex than those associated with conventional investigational medicinal products, and may require a structured approach to nonclinical data, trial documentation and risk assessment.

Where ICH S12 Creates an Underestimated Compliance Surface

ICH S12 applies to a broad range of gene therapy products, including purified nucleic acids such as plasmids and RNA, genetically modified microorganisms such as viruses and bacteria that express transgenes, ex vivo genetically modified human cells, and products that edit the host genome without relying on specific transcription or translation — including non-viral delivery of nucleases and guide RNAs. The principles of the guideline may also be relevant to oncolytic viruses that are not engineered to express a transgene, even where such products are not classified as gene therapy products in every jurisdiction. For a clinical site such as the Medical University of Gdańsk, this illustrates that product categories encountered in academic trial portfolios may be broader than the label “gene therapy” alone suggests.

The guideline describes nonclinical biodistribution as the study of the location, persistence and mobilisation of a gene therapy product following in vivo administration. Biodistribution data can contribute to the interpretation of nonclinical pharmacology and toxicology studies supporting early-phase clinical development. Where an investigational gene therapy product is used at a clinical site, a clear understanding of the relevant nonclinical data package — including biodistribution considerations disclosed by the sponsor — may support a more informed site-level assessment of product-specific risks. This may be relevant to the site’s review of trial documentation and to the risk information considered in submissions to the ethics committee and competent authority under Regulation (EU) 536/2014.

The Data Architecture Problem Behind the Compliance Problem

Academic trial portfolios are not always managed as structured regulatory datasets. Trial registration records in CTIS, ClinicalTrials.gov and, for earlier or non-EU/EEA contexts, EudraCT are often treated primarily as administrative outputs rather than as queryable sources of regulatory intelligence. In practice, information relevant to product characterisation, nonclinical development and safety oversight may be distributed across registration records, trial documentation and sponsor submissions. Where this information is not systematically linked, a clinical site may have limited visibility into product-specific considerations — including those relevant to gene therapy products — even where the underlying information exists within the regulatory submission chain. For institutions managing broad and therapeutically diverse portfolios, this can create an operational challenge in maintaining a consolidated view of trial-related risks.

Vestango’s monitoring approach is designed to help address this type of information fragmentation. By drawing on publicly available regulatory and trial-related sources, including CTIS, EudraVigilance and other relevant registries and databases, it aims to identify relevant changes in trial records, safety information and product-related documentation. Where a trial registration record changes — for example, through a protocol amendment, an updated investigational medicinal product dossier or a safety-related update — the change can be captured, classified and assessed against the applicable regulatory context. For gene therapy trials, such an assessment may include the product’s relevance to ICH S12, the availability and completeness of relevant nonclinical documentation, and the safety-reporting arrangements applicable to the investigational product under the relevant clinical trial authorisation.

Parallel Signals from the Broader Trial Portfolio

The clinical trial activity associated with MUG extends beyond gene therapy. Publicly available trial information indicates research interests across areas such as haematology, endocrinology and perioperative medicine. Depending on the specific studies and their design, such a portfolio may include trials involving reduced-dose direct oral anticoagulants, diagnostic or screening protocols, and assessments of respiratory function in surgical populations. Each study may raise different questions relating to trial classification, investigational medicinal product use, safety monitoring and the documentation required under the applicable clinical trial framework.

Where a study involves a pharmacokinetic comparison of anticoagulants in an oncology population, cardiac safety considerations may be relevant to the overall development programme, subject to the product, population, endpoints and study design. Similarly, the classification of a diagnostic or screening protocol under Regulation (EU) 536/2014 depends on its precise objectives, interventions and endpoints. It is therefore important that sponsors and sites assess each study on its own facts rather than relying on broad product or therapeutic-area categories.

These distinctions can have commercial consequences. An academic centre managing a portfolio of active trials may simultaneously be supporting studies with different regulatory characteristics, documentation requirements and risk profiles. Where classification or documentation questions are identified late, they may complicate subsequent regulatory interactions, due diligence or development planning. Early alignment between sponsors, investigators and site teams on trial objectives, IMP use and applicable requirements can therefore support a more consistent and defensible trial portfolio.

.

GMP and Safety Signal Context: What the Recent Recall Environment Reveals

Product-quality and recall-related information may also be relevant to clinical trial operations, particularly where an investigational medicinal product, comparator or co-administered standard-of-care product is affected. Publicly available safety and quality communications — including recall notices, field safety corrective actions and product-defect notifications — can provide useful signals for sponsors and clinical sites, although their relevance to a particular trial depends on the product, its role in the study and the applicable trial arrangements.

Where a trial-related product is subject to a recall or correction, sponsors and investigators should assess the potential impact on participant safety, product accountability, trial conduct and documentation. The appropriate response will depend on the nature of the issue, the product’s use in the trial and the requirements set out in the clinical trial authorisation, protocol and applicable quality system. Early identification of such signals can support timely assessment and, where necessary, communication with the relevant ethics committee, competent authority or sponsor.

Vestango’s monitoring approach is designed to support this type of review by bringing together publicly available trial, safety and product-quality information from relevant registries and databases. Where relevant signals are identified, they can be assessed in the context of a trial portfolio to help internal teams determine whether further review or follow-up is warranted.

What This Means for Sponsors and In-Licensing Counterparties

For a commercial sponsor considering MUG as a Phase I or Phase II site for a gene therapy or advanced therapy medicinal product, the site’s experience, infrastructure and approach to trial governance may be relevant due diligence considerations. Under the EU ATMP framework and in light of the nonclinical considerations set out in ICH S12, sponsors may benefit from assessing how a prospective site reviews product-specific documentation, manages trial-related information and supports the safety and quality arrangements applicable to the investigational product. This is distinct from assigning direct ICH S12 or GVP Module VI obligations to the site: those frameworks primarily operate at the level of product development, marketing authorisation and post-authorisation pharmacovigilance, while investigational products are governed by the applicable clinical trial framework.

In an in-licensing or partnering context, where early-phase clinical data may contribute to asset valuation, the completeness and internal consistency of the underlying trial documentation can be relevant to regulatory due diligence. Gaps or inconsistencies identified at a later stage may require additional clarification, documentation or remediation, with potential consequences for development timelines and transaction discussions. The scale of any such impact will, however, depend on the product, study design, regulatory strategy and the nature of the issue identified.

The Resolution Path

The regulatory and operational questions associated with an academic medical centre’s trial portfolio can often be addressed through a structured review. A first step may be a trial portfolio review that compares relevant records in CTIS, ClinicalTrials.gov and, where applicable, historical EudraCT records with the centre’s active or recently completed studies. Such a review can help identify, for each study, the applicable regulatory context, the role of any investigational medicinal product, relevant safety-monitoring arrangements and product-specific considerations — including, where relevant, the nonclinical biodistribution issues addressed by ICH S12. It may also consider whether product-quality or recall-related information could be relevant to trial-related products, subject to the specific product and study circumstances.

The next step is to translate the resulting overview into a prioritised action plan. Rather than a generic compliance checklist, this can take the form of a structured sequence of follow-up activities, linked to the relevant trial documentation, regulatory context and internal governance processes. Vestango can conduct an initial review and provide an initial set of structured observations as a starting point for a more detailed, case-specific analysis.

If your institution or sponsored programme conducts clinical trials at academic centres operating under Regulation (EU) 536/2014 and would benefit from a structured review of trial classification, investigational product documentation, safety-monitoring arrangements, product-specific nonclinical considerations and relevant product-quality signals, contact Vestango. Vestango combines regulatory analysis with structured, queryable trial and safety-related data, supporting internal teams in forming their own evidence-based conclusions.

The analysis in this article draws on publicly available regulatory data, published guidelines, and the accumulated experience of Vestango Life Sciences in EU and Polish regulatory affairs. It reflects patterns we observe — not universal conclusions. Every regulatory situation is product-specific, market-specific, and jurisdiction-specific. What applies to one portfolio may not apply to yours. If any of the issues raised here resonate with your situation, the right next step is a structured, case-specific conversation — not the application of general conclusions. With our founder Paweł Wojtaszczyk, Ph.D. Eng., we work at the intersection of data science and regulatory affairs, translating that combination into real market implementations. We solve problems and build companies operating in the life sciences market. Contact Vestango.

Our website uses cookies, which are saved on the disk of the user's end device in order to facilitate navigation and adapt the website to the user's preferences. Detailed information about cookies can be found in the Privacy Policy. Blocking the saving of cookies on the end device or deleting them is possible after properly configuring the settings of the web browser. You can find more about blocking and deleting cookies in the Privacy Policy. Blocking the possibility of saving cookies may cause difficulties or lack of operation of some website functions. Failure to change the web browser settings to settings blocking the saving of cookies is tantamount to consenting to their saving.

Accept